Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

Neurology

Volumn 77, Issue 22, 2011, Pages 1998-2000

  Wiebenga, O T ^a   Hulst, H E ^a   Kooi, E J ^a   Killestein, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LETTER; MEMORY DISORDER; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; NEUROTRANSMISSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); FEMALE; MALE; NOTE;

CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; MEMORY DISORDERS; PIPERIDINES;

EID: 82955175428     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318239c242     Document Type: Letter

References (5)

1. LB Krupp C Christodoulou P Melville Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis Neurology 76 2011 1500 1507
2. LB Krupp C Christodoulou P Melville WF Scherl WS MacAllister LE Elkins Donepezil improved memory in multiple sclerosis in a randomized clinical trial Neurology 63 2004 1579 1585
3. C Christodoulou WS MacAllister NA McLinskey LB Krupp Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? CNS Drugs 22 2008 87 97
4. MR Farlow S Salloway PN Tariot Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study Clin Ther 32 2001 1234 1251
5. EJ Kooi M Prins N Bajlic Cholinergic imbalance in the multiple sclerosis hippocampus Acta Neuropathol 2011 Epub